News

Adagio Medical Closes Financing of $19 Million Upfront; Positions Company to Advance Purpose-Built Technology for Treatment of Ventricular Tachycardia

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the closing of its previously announced private placement (https://investors.adagiomedical.com/news-releases/news-release-details/adagio-medical-announces-pricing-50-million-private-placement), led by existing investors and new healthcare-dedicated institutional investors.

10/20/2025

Adagio Medical Announces Pricing of up to $50 Million Private Placement of Securities

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or the “Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with certain accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants (“Warrants”) that is expected to result in approximately $19 million.

10/15/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Adagio Medical Holdings, Inc. (ADGM) a buy, sell, or hold?

Adagio Medical Holdings, Inc. (ADGM) can sell. Click on Rating Page for detail.

What is Adagio Medical Holdings, Inc.'s stock price?

The price of Adagio Medical Holdings, Inc. (ADGM) is 1.14 and it was updated on 2025-10-31 13:00:28.

Is Adagio Medical Holdings, Inc. (ADGM) overvalued or undervalued?

Currently Adagio Medical Holdings, Inc. (ADGM) is in undervalued.

News

From:

To:

News
Adagio Medical Unveils Preliminary Acute Results from FULCRUM-VT U.S. Pivotal Study in Late Breaking Session at VT Symposium LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced preliminary acute (within 7 days) safety and efficacy results from the Adagio's FULCRUM-VT Study evaluating Ultralow Temperature Cryoablation (“ULTC”) for the treatment of Sustained Monomorphic Ventricular Tachycardia (“SMVT”) in patients with both ischemic and nonischemic. Fri, Oct. 10, 2025
Adagio Medical, Inc. Announces Completion of Enrollment for FULCRUM-VT Pivotal Clinical Trial Evaluating Ultra-Low Temperature Cryoablation for Ventricular Tachycardia LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the completion of enrollment of the FULCRUM-VT Pivotal U.S. Food and Drug Administration (“FDA”) Investigational Device Exemption (“IDE”) study evaluating the Company's vCLASTM Cryoablation System (“vCLAS” or “vCLAS System”) for ablation of monomorphic ventricular tachycard. Wed, Oct. 01, 2025
Adagio Medical FULCRUM-VT U.S. Pivotal Study Acute Results to be Presented in Late-Breaking Session at VT Symposium LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that acute results from the Company's FULCRUM-VT U.S. pivotal study have been accepted for presentation in a late-breaking clinical science session at The 20th Annual International Symposium on Ventricular Arrhythmias, being held from October 10- 11, 2025 at the Philadelphi. Thu, Sep. 18, 2025
Adagio Medical Expands Chief Business Officer Deborah Kaster's Role to Include Chief Financial Officer Responsibilities LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the Company's Chief Business Officer, Deborah Kaster's, responsibilities have been expanded to include the role of Chief Financial Officer, effective September 5, 2025. Ms. Kaster succeeds Dan George, who served as the Company's interim Chief Financial Officer since Ap. Mon, Sep. 08, 2025
Adagio Medical Reports Second Quarter 2025 Results LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Surpassed 85% enrollment in the FULCRUM-VT pivotal study of the Company's vCLAS™ Cryoablation System. The study, which seeks to enroll 206 patients with either ischemic or non-ischemic. Wed, Aug. 13, 2025

SEC Filings

SEC Filings
Adagio Medical Holdings, Inc. (ADGM) - D SEC Filings 10/29/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 10/24/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 10/24/2025
Adagio Medical Holdings, Inc. (ADGM) - 4 SEC Filings 10/22/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 10/20/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 10/20/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 10/15/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 10/15/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 10/10/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 10/10/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 10/01/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 10/01/2025
Adagio Medical Holdings, Inc. (ADGM) - 3 SEC Filings 09/30/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 09/08/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 09/08/2025
Adagio Medical Holdings, Inc. (ADGM) - SCHEDULE 13G/A SEC Filings 08/26/2025
Adagio Medical Holdings, Inc. (ADGM) - SCHEDULE 13G/A SEC Filings 08/14/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 08/14/2025
Adagio Medical Holdings, Inc. (ADGM) - 10-Q - Quarterly Report SEC Filings 08/14/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 08/13/2025
Adagio Medical Holdings, Inc. (ADGM) - SCHEDULE 13G SEC Filings 08/12/2025
Adagio Medical Holdings, Inc. (ADGM) - SCHEDULE 13G/A SEC Filings 05/15/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 05/15/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 05/15/2025
Adagio Medical Holdings, Inc. (ADGM) - 10-Q - Quarterly Report SEC Filings 05/15/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 05/01/2025
Adagio Medical Holdings, Inc. (ADGM) - 10-K/A - Current report SEC Filings 04/30/2025
Adagio Medical Holdings, Inc. (ADGM) - 3 SEC Filings 04/28/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 04/23/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 04/23/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 04/02/2025
Adagio Medical Holdings, Inc. (ADGM) - S-8 SEC Filings 03/27/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 03/27/2025
Adagio Medical Holdings, Inc. (ADGM) - 10-K - Current report SEC Filings 03/27/2025
Adagio Medical Holdings, Inc. (ADGM) - 4 SEC Filings 03/21/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 03/17/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 03/17/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 03/04/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 03/04/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 02/28/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 02/28/2025
Adagio Medical Holdings, Inc. (ADGM) - SCHEDULE 13G/A SEC Filings 02/14/2025
Adagio Medical Holdings, Inc. (ADGM) - 4 SEC Filings 02/14/2025
Adagio Medical Holdings, Inc. (ADGM) - 4 SEC Filings 02/13/2025
Adagio Medical Holdings, Inc. (ADGM) - EFFECT SEC Filings 02/10/2025
Adagio Medical Holdings, Inc. (ADGM) - EFFECT SEC Filings 02/10/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 02/07/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 02/05/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 02/05/2025
Adagio Medical Holdings, Inc. (ADGM) - S-1/A SEC Filings 02/04/2025
Adagio Medical Holdings, Inc. (ADGM) - S-1 SEC Filings 01/14/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 01/06/2025
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 01/06/2025
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 12/23/2024
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 12/23/2024
Adagio Medical Holdings, Inc. (ADGM) - 3 SEC Filings 12/20/2024
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 12/16/2024
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 12/16/2024
Adagio Medical Holdings, Inc. (ADGM) - EFFECT SEC Filings 11/26/2024
Adagio Medical Holdings, Inc. (ADGM) - EFFECT SEC Filings 11/26/2024
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 11/26/2024
Adagio Medical Holdings, Inc. (ADGM) - POS AM SEC Filings 11/25/2024
Adagio Medical Holdings, Inc. (ADGM) - POS AM SEC Filings 11/22/2024
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 11/14/2024
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 11/14/2024
Adagio Medical Holdings, Inc. (ADGM) - 10-Q - Quarterly Report SEC Filings 11/14/2024
Adagio Medical Holdings, Inc. (ADGM) - SC 13G SEC Filings 11/13/2024
Adagio Medical Holdings, Inc. (ADGM) - POS AM SEC Filings 11/08/2024
Adagio Medical Holdings, Inc. (ADGM) - 8-K/A - Current report SEC Filings 11/04/2024
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 11/01/2024
Adagio Medical Holdings, Inc. (ADGM) - S-8 SEC Filings 10/08/2024
Adagio Medical Holdings, Inc. (ADGM) - 4 SEC Filings 10/01/2024
Adagio Medical Holdings, Inc. (ADGM) - EFFECT SEC Filings 09/20/2024
Adagio Medical Holdings, Inc. (ADGM) - EFFECT SEC Filings 09/20/2024
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 09/19/2024
Adagio Medical Holdings, Inc. (ADGM) - S-1 SEC Filings 09/13/2024
Adagio Medical Holdings, Inc. (ADGM) - 10-Q - Quarterly Report SEC Filings 08/26/2024
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 08/19/2024
Adagio Medical Holdings, Inc. (ADGM) - 8-K/A - Current report SEC Filings 08/14/2024
Adagio Medical Holdings, Inc. (ADGM) - SC 13G SEC Filings 08/12/2024
Adagio Medical Holdings, Inc. (ADGM) - 8-K - Current report SEC Filings 08/06/2024
Adagio Medical Holdings, Inc. (ADGM) - 4 SEC Filings 08/02/2024
Adagio Medical Holdings, Inc. (ADGM) - CERT SEC Filings 08/01/2024
Adagio Medical Holdings, Inc. (ADGM) - 8-A12B SEC Filings 08/01/2024
Adagio Medical Holdings, Inc. (ADGM) - 3 SEC Filings 08/01/2024
Adagio Medical Holdings, Inc. (ADGM) - 425 SEC Filings 07/26/2024
Adagio Medical Holdings, Inc. (ADGM) - 425 SEC Filings 07/23/2024
Adagio Medical Holdings, Inc. (ADGM) - EFFECT SEC Filings 07/15/2024
Adagio Medical Holdings, Inc. (ADGM) - 424B3 SEC Filings 07/12/2024
Adagio Medical Holdings, Inc. (ADGM) - UPLOAD SEC Filings 07/11/2024
Adagio Medical Holdings, Inc. (ADGM) - S-4/A SEC Filings 07/11/2024
Adagio Medical Holdings, Inc. (ADGM) - CORRESP SEC Filings 07/11/2024
Adagio Medical Holdings, Inc. (ADGM) - 425 SEC Filings 07/02/2024
Adagio Medical Holdings, Inc. (ADGM) - S-4/A SEC Filings 06/25/2024
Adagio Medical Holdings, Inc. (ADGM) - CORRESP SEC Filings 06/25/2024
Adagio Medical Holdings, Inc. (ADGM) - 425 SEC Filings 06/25/2024
Adagio Medical Holdings, Inc. (ADGM) - 425 SEC Filings 06/11/2024
Adagio Medical Holdings, Inc. (ADGM) - 425 SEC Filings 06/03/2024
Adagio Medical Holdings, Inc. (ADGM) - UPLOAD SEC Filings 05/30/2024
Adagio Medical Holdings, Inc. (ADGM) - 425 SEC Filings 05/16/2024
Adagio Medical Holdings, Inc. (ADGM) - S-4/A SEC Filings 05/13/2024
Adagio Medical Holdings, Inc. (ADGM) - CORRESP SEC Filings 05/13/2024
Adagio Medical Holdings, Inc. (ADGM) - UPLOAD SEC Filings 05/03/2024
Adagio Medical Holdings, Inc. (ADGM) - 425 SEC Filings 05/02/2024
Adagio Medical Holdings, Inc. (ADGM) - S-4 SEC Filings 04/19/2024
Adagio Medical Holdings, Inc. (ADGM) - CORRESP SEC Filings 04/18/2024
Adagio Medical Holdings, Inc. (ADGM) - 425 SEC Filings 03/25/2024
Adagio Medical Holdings, Inc. (ADGM) - UPLOAD SEC Filings 03/12/2024
Adagio Medical Holdings, Inc. (ADGM) - DRS SEC Filings 02/14/2024

Press Releases

StockPrice Release
Adagio medical closes financing of $19 million upfront; positions company to advance purpose-built technology for treatment of ventricular tachycardia 10/20/2025
Adagio medical announces pricing of up to $50 million private placement of securities 10/15/2025
Adagio medical unveils preliminary acute results from fulcrum-vt u.s. pivotal study in late breaking session at vt symposium 10/10/2025
Adagio medical, inc. announces completion of enrollment for fulcrum-vt pivotal clinical trial evaluating ultra-low temperature cryoablation for ventricular tachycardia 10/01/2025
Adagio medical fulcrum-vt u.s. pivotal study acute results to be presented in late-breaking session at vt symposium 09/18/2025
Adagio medical expands chief business officer deborah kaster's role to include chief financial officer responsibilities 09/08/2025
Adagio medical reports second quarter 2025 results 08/13/2025
Adagio medical to present at the bofa securities 2025 health care conference 05/07/2025
Adagio medical holdings, inc. receives fda breakthrough device designation for the vclastm cryoablation system 04/17/2025
Adagio medical appoints deborah kaster as chief business officer 03/31/2025
Adagio medical reports fourth quarter and full year 2024 results 03/31/2025
Adagio medical provides clinical and business updates 03/17/2025
Adagio medical announces strategic restructuring to accelerate us pivotal ide trial and product innovation 02/28/2025
Adagio medical announces completion of first procedures in fulcrum-vt u.s. fda pivotal ide of ventricular tachycardia cryoablation system 10/24/2024
Adagio medical announces participation in the 19th annual international symposium on ventricular arrhythmias 10/07/2024

More Headlines

News
Adagio Medical to Present at the BofA Securities 2025 Health Care Conference LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the BofA Securities Health Care Conference on Tuesday, May 13, 2025, at 9:20 a.m. PT at the Encore Hotel in Las Vegas, NV. Presentation Information A live and recorded webcast of the presentation will be available at: https://bofa.verac. 05/07/2025
Adagio Medical Holdings, Inc. Receives FDA Breakthrough Device Designation for the vCLASTM Cryoablation System LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that it has received Breakthrough Device designation from the U.S. Food and Drug Administration (“FDA”) for its vCLASTM Cryoablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia (“VT”) in patients with ischemic or non. 04/17/2025
Adagio Medical Appoints Deborah Kaster as Chief Business Officer LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical (Nasdaq: ADGM), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, is pleased to announce the appointment of Deborah Kaster as Chief Business Officer (CBO). Kaster brings more than 25 years of leadership experience in strategy, mergers and acquisitions, corporate finance, investor relations and strategic communications in the medical technology sector. Most recently, Kaster served as Vice President of. 03/31/2025
Adagio Medical Reports Fourth Quarter and Full Year 2024 Results LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights: Reported total company revenue of $137 thousand in the fourth quarter of 2024, compared to $78 thousand in the fourth quarter of 2023. Full year revenue for 2024 was $0.6 million compared to $0.3. 03/31/2025
Adagio Medical Provides Clinical and Business Updates LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies, provided updates today on the progress in its streamlined focus on leadership in ventricular tachycardia (“VT”) solutions. Recent Business Highlights: The Company will participate in the scientific program of the 2025 European Heart Rhythm Association (the “Association”) Annual Meeting to be held from March 30 through April 1 in Vienna, Austr. 03/17/2025
Adagio Medical Announces Strategic Restructuring to Accelerate US Pivotal IDE Trial and Product Innovation LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced a corporate restructuring and realignment of resources to prioritize its FULCRUM-VT US pivotal investigational device exemption (“Pivotal IDE”) clinical trial activities and its new product design optimization program. “After a comprehensive strategic review, we are doubling down on the pri. 02/28/2025
Adagio Medical Announces Completion of First Procedures in FULCRUM-VT U.S. FDA Pivotal IDE of Ventricular Tachycardia Cryoablation System LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; “Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies, today announced the completion of the first procedures in FULCRUM-VT U.S. Food and Drug Administration (FDA) Pivotal IDE study of Adagio's VT Cryoablation System. Procedures were performed by Professor William G. Stevenson, MD, at Vanderbilt University Medical Center in Nashville, TN and Dr. J. David Burkhardt at. 10/24/2024
Adagio Medical Announces Participation in the 19th Annual International Symposium on Ventricular Arrhythmias LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced its sponsorship and participation in the 19th Annual International Symposium on Ventricular Arrhythmias, to be held at the New York Marriott at the Brooklyn Bridge on October 11-12, 2024. In addition to participating in the commercial exhibition, Adagio's proprietary Ultra-Low Temperature C. 10/07/2024

Unlock

ADGM Ratings Summary

ADGM Quant Ranking

Is Adagio Medical Holdings, Inc. (ADGM) a buy, sell, or hold?

What is Adagio Medical Holdings, Inc.'s stock price?

Is Adagio Medical Holdings, Inc. (ADGM) overvalued or undervalued?

Adagio Medical to Present at the BofA Securities 2025 Health Care Conference

Adagio Medical Holdings, Inc. Receives FDA Breakthrough Device Designation for the vCLASTM Cryoablation System

Adagio Medical Appoints Deborah Kaster as Chief Business Officer

Adagio Medical Reports Fourth Quarter and Full Year 2024 Results

Adagio Medical Provides Clinical and Business Updates

Adagio Medical Announces Strategic Restructuring to Accelerate US Pivotal IDE Trial and Product Innovation

Adagio Medical Announces Completion of First Procedures in FULCRUM-VT U.S. FDA Pivotal IDE of Ventricular Tachycardia Cryoablation System

Adagio Medical Announces Participation in the 19th Annual International Symposium on Ventricular Arrhythmias